DOV lowers its 2024 adjusted EPS view to $8.08-$8.18 for 2024 from $9.05-$9.20 to exclude the impacts of the ESG business ...

Impinj’s PI third-quarter 2024 adjusted earnings of 56 cents per share beat the Zacks Consensus Estimate by 19.15%. The ...

CNQ topped the Zacks Consensus Estimate for earnings in three of the last four quarters and missed in the other.

Building a successful investment portfolio takes skill and hard work, no matter if you're a growth, value, income, or momentum-focused investor. How do you find the right combination of stocks that ...

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investment analysts at Zacks Research upped their Q3 2025 earnings per share estimates for Allegion in a research report ...

Stock analysts at Zacks Research increased their Q1 2025 earnings estimates for shares of Newmont in a research note issued ...

Cleveland-Cliffs (CLF) reachead $13.46 at the closing of the latest trading day, reflecting a -1.32% change compared to its last close.

Bristol Myers (BMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks.com users have recently been watching Celsius (CELH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Recently, Zacks.com users have been paying close attention to Oracle (ORCL). This makes it worthwhile to examine what the ...

Recently, Zacks.com users have been paying close attention to Visa (V). This makes it worthwhile to examine what the stock has in store.